Euro Manganese plans restart of pilot plant to produce samples

|

Published 15-JUN-2021 10:57 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Euro Manganese Inc. (TSX-V/ASX:EMN), management has announced its plan to restart the company’s pilot plant to produce high-purity manganese samples for prospective customers.

The restart of the pilot plant is an important development because it will provide potential end-users with products to trial, laying the foundation for possible offtake agreements.

Euro Manganese Inc. is a battery materials company whose principal focus is advancing the development of the Chvaletice Manganese Project.

The proposed project entails reprocessing a substantial manganese deposit hosted in mine tailings from a decommissioned mine located in the Czech Republic, relatively close to industrial hubs in Europe, where there is growing demand for EV battery raw materials.

The company has engaged Changsha Research Institute for Mining and Metallurgy Co. Ltd. (CRIMM), the original operators of the pilot plant, to restart the facility with delivery of product samples targeted for the fourth quarter of 2021.

The samples will be used by prospective customers to accelerate their supply chain qualification work.

CRIMM is also the lead contractor for the Demonstration Plant (DP) that is currently being fabricated in China for delivery and installation at the Chvaletice Manganese Project site in the Czech Republic later this year.

Aerial shot of tailings.
Aerial shot of tailings.

Demonstration plant to mirror commercial scale process

The DP will recycle tailings material to produce battery-grade manganese products using the same process proposed for the full-scale commercial plant where production is anticipated to commence in late 2024/early 2025.

The pilot plant, which in 2018 produced ultra-high-purity manganese samples as part of the project’s Preliminary Economic Assessment (PEA) metallurgical test work program, will be refurbished and restarted to prepare an initial batch of approximately 50 kilograms of high-purity electrolytic manganese metal and 150 kilograms of high-purity manganese sulphate monohydrate.

These product samples will be used by prospective customers for supply chain qualification, which involves thorough testing and evaluation of battery raw materials prior to approval for use by cathode, battery and electric vehicle manufacturers.

In discussing industry dynamics and the significance of these developments for Euro Manganese, chief executive Marco Romero said, “Demand for sustainably-produced, battery-grade manganese is increasing rapidly and there simply isn’t enough production capacity in the world to meet it today.

“New producers need to come on stream soon and undergo rigorous supply chain qualification of their products.

“The restart of our pilot plant will help us better service several prospective customers’ near term objectives to pre-qualify new producers like ourselves.

“With the restart of our pilot plant, we will be able to move more quickly in delivering finished-product samples, while also enabling the follow-on in early 2022 with larger samples from our Demonstration Plant.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X